Second study shows ambulatory BP patterns not tied to cognitive impairment or frailty in CKD patients
The decision to stop the trial was made based on positive efficacy data following a recommendation from the study’s independent DMC.
DaVita Inc. and Fresenius Medical Care North America (FMCNA) jointly announced they are collaborating in response to the COVID-19 pandemic to offer isolation capacity for dialysis patients who are or may be infected with the novel coronavirus that causes the disease. The companies, which are the largest providers of dialysis in the United States, also…
But high average blood pressure on 24-hour test strongly predicts child’s cardiac, kidney disease risk.
Physicians at the University of California Irvine describe an unusual presentation of the novel coronavirus illness in a 56-year-old man. The case is believed to be among the first COVID-19 cases in the United States.
The National Kidney Foundation issued a statement today urging patients on dialysis to continue undergoing treatments during the COVID-19 pandemic. “It is extremely important for kidney patients to continue with their regularly scheduled dialysis treatments and take extra precautions when visiting the facilities to best protect their health,” said Joseph Vassalotti, MD, Chief Medical Officer for NKF. “Skipping…
Glecaprevir/pibrentasvir for 8 to 12 weeks is an effective and well-tolerated treatment for patients with chronic hepatitis C virus and chronic kidney disease stage 4 or 5.
The FDA has granted Fast Track designation for empagliflozin (Jardiance; Boehringer Ingelheim and Lilly) to reduce the risk of kidney disease progression and cardiovascular (CV) death in adults with chronic kidney disease.
The prescribing information for Talzenna (talazoparib; Pfizer) has been updated to include recommendations for patients with severe renal impairment.
The Centers for Disease Control and Prevention has updated the guidance for evaluation of persons under investigation for coronavirus disease 2019 (COVID-19), expanding the criteria to a wider group of symptomatic patients.